ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products

11 Oct 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial

06 Oct 2022 16:15:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit

23 Sep 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Second Quarter 2022 Financial Results

09 Aug 2022 16:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

03 Aug 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

27 Jul 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors

12 Jul 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma

08 Jun 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

19 May 2022 08:30:01 By Nasdaq GlobeNewswire

Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal

09 May 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2022 Financial Results

04 May 2022 16:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer

28 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022

27 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma

27 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products

14 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal

13 Apr 2022 09:00:02 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences

12 Apr 2022 08:30:01 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma

23 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma

10 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Report

01 Mar 2022 08:30:00 By Nasdaq GlobeNewswire